Enovis Corp
$ 23.96
1.18%
09 Jun - close price
- Market Cap 1,373,444,000 USD
- Current Price $ 23.96
- High / Low $ 24.58 / 23.50
- Stock P/E N/A
- Book Value 25.66
- EPS -19.89
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE -0.55 %
- 52 Week High 36.82
- 52 Week Low 20.82
About
Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.
Analyst Target Price
$43.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-07 | 2023-08-03 |
| Reported EPS | 0.89 | 0.95 | 0.75 | 0.79 | -0.98 | 0.98 | 0.73 | 0.62 | -1.32 | 0.79 | 0.56 | 0.61 |
| Estimated EPS | 0.81 | 0.8237 | 0.65 | 0.72 | 0.7438 | 0.9157 | 0.61 | 0.59 | 0.11 | 0.74 | 0.54 | 0.52 |
| Surprise | 0.08 | 0.1263 | 0.1 | 0.07 | -1.7238 | 0.0643 | 0.12 | 0.03 | -1.43 | 0.05 | 0.02 | 0.09 |
| Surprise Percentage | 9.8765% | 15.3333% | 15.3846% | 9.7222% | -231.7558% | 7.022% | 19.6721% | 5.0847% | -1300% | 6.7568% | 3.7037% | 17.3077% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.85 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ENOV
2026-06-08 12:59:00
Enovis Corporation has launched the DonJoy Spinamic Hybrid Scoliosis Brace in the U.S., designed to treat adolescent idiopathic scoliosis. This device combines rigid corrective elements with a flexible mesh design, offering a more comfortable and efficient treatment option. Despite a recent 25% stock decline, Enovis shares rose nearly 10% this past week, and analysts predict profitability for the company this year.
2026-06-08 12:39:00
Enovis Corporation has launched the DonJoy Spinamic® Hybrid Scoliosis Brace, designed to offer an optimal balance of corrective performance and improved wearability for children and teens with adolescent idiopathic scoliosis (AIS). This innovative brace integrates rigid corrective elements into a breathable, adjustable design, aiming to enhance clinical outcomes and patient compliance. Available in 10 off-the-shelf sizes, the brace allows for fitting, imaging, and adjustment in a single visit, addressing the previous trade-offs between effective treatment and patient comfort.
2026-06-08 09:39:00
Enovis (ENOV) shares increased by 9.6% after the company exceeded Q1 2026 revenue and adjusted EPS targets and reaffirmed its full-year outlook. Shareholders also approved amendments to the incentive plan, aligning leadership rewards with operational progress. This performance and enhanced incentives are shaping a new investment narrative, despite historical challenges like losses and weak returns on invested capital.
2026-06-06 16:08:48
Enovis (ENOV) shares have recently rebounded, showing an increase of about 4% over the past day and 5% over the past week, though year-to-date and longer-term returns remain weak. Despite lingering caution from investors, Simply Wall St's analysis suggests Enovis is undervalued by 46.8%, with a fair value estimate of $44.73 compared to its current price of $23.78. This valuation is driven by expectations of growth, rising profitability from next-generation technologies, and a higher future earnings multiple, while acknowledging risks like integration challenges from recent acquisitions.
2026-06-05 22:00:00
Enovis (ENOV) shares have dropped significantly, contrasting with the S&P 500's gains. The company is deemed risky due to spiraling revenue, negative return on invested capital from previous growth initiatives, and a continued decline in ROIC from new investments. The article suggests Enovis doesn't pass a quality test and recommends investors consider alternative stocks.
2026-06-04 17:43:00
Enovis Corporation (NYSE: ENOV) reported Q1 2026 revenue of $589.2 million, surpassing analyst expectations, and achieved an adjusted EPS of $0.89. The company also maintained its full-year 2026 outlook for revenue, adjusted EBITDA, adjusted EPS, and free cash flow conversion. Additionally, shareholders approved an amendment to the company's Omnibus Incentive Plan, expanding available shares for employee equity and raising the compensation cap for independent directors.
